Merck to Present Data on Mavenclad and Rebif in Relapsing Forms of MS at EAN

Merck, a leading science and technology company, will present data from its neurology and immunology portfolio at the 4th Congress of the European Academy of Neurology (EAN), taking place from June 16-19, in Lisbon, Portugal. Merck will present a total of 14 abstracts in the area of relapsing multiple sclerosis (RMS), including a post-hoc analysis of the Phase III CLARITY study, investigating whether the beneficial clinical and magnetic resonance imaging (MRI) effects of MAVENCLAD are consistent in older (>50 years) and younger (≤50) adult patients with relapsing remitting MS (RRMS). Data presented at the congress will also provide further insights into the benefit-risk profile of MAVENCLAD in patients with relapsing MS with high disease activity, using Multi-Criteria Decision Analysis, an EMA-recommended methodology used to indirectly compare the benefit-risk profile between treatments. A separate post hoc analysis of patients in the ONWARD study evaluates the efficacy of MAVENCLAD as add-on to interferon beta-1a in patients with secondary progressive MS (SPMS) with relapses, compared to patients with RRMS from the same study.

Additionally, data presentations on Rebif (interferon beta-1a) include analysis of MRI in MS (MAGNIMS) score to predict long-term clinical disease activity (CDA)-free status and disability progression following treatment with Rebif. In line with Merck’s MS Inside Out campaign aiming to better understand patients with MS, results of the Merck-sponsored MS in the 21st Century International Unmet Needs Survey show that MS patients have substantially different perceptions of the current unmet needs in MS compared to healthcare professionals (HCPs). Identification and understanding of these differences could lead to an improved dialogue between HCPs and patients, which is integral to finding appropriate individualised treatment approaches for each patient. – Medical Buyer Bureau